The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Why is big Pharma getting out of antibacterial drug discovery?
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Infectious Diseases: Considerations for the 21st Century
Fauci, A. S. (2001) · Clinical Infectious Diseases · doi:10.1086/319235 · Cited by 443
New (and not so new) antibacterial targets – from where and when will the novel drugs come?
Projan, S. J. (2002) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(02)00197-2 · Cited by 122
Self-citationHackbarth, C. J., Chen, D. Z., Lewis, J. G., Clark, K., Mangold, J. B., Cramer, J. A., Margolis, P. S., Wang, W., Koehn, J., Wu, C., et al. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.9.2752-2764.2002 · Cited by 115
Cited by
Origins and evolution of antibiotic resistance
Davies, J., & Davies, D. (2010) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00016-10 · Cited by 5,784
Antibacterial resistance worldwide: causes, challenges and responses
Levy, S. B., & Marshall, B. (2004) · Nature Medicine · doi:10.1038/nm1145 · Cited by 4,052
The evolving role of natural products in drug discovery
Koehn, F. E., & Carter, G. T. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1657 · Cited by 2,572
Antibiotics and Bacterial Resistance in the 21st Century
Fair, R. J., & Tor, Y. (2014) · Perspectives in Medicinal Chemistry · doi:10.4137/pmc.s14459 · Cited by 1,955
Spellberg, B., Guidos, R., Gilbert, D., Bradley, J., Boucher, H. W., Scheld, W. M., Bartlett, J. G., Edwards, J., & the Infectious Diseases Society of America (2008) · Clinical Infectious Diseases · doi:10.1086/524891 · Cited by 1,642
Metallo-β-Lactamases: the Quiet before the Storm?
Walsh, T. R., Toleman, M. A., Poirel, L., & Nordmann, P. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.2.306-325.2005 · Cited by 1,431
Resistance to Antibiotics: Are We in the Post-Antibiotic Era?
Alanis, A. J. (2005) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.06.009 · Cited by 1,417
Challenges of Antibacterial Discovery
Silver, L. L. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00030-10 · Cited by 1,376
The antibiotic resistome: the nexus of chemical and genetic diversity
Wright, G. D. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1614 · Cited by 1,365
Talbot, G. H., Bradley, J., Edwards, J. E., Gilbert, D., Scheld, M., & Bartlett, J. G. (2006) · Clinical Infectious Diseases · doi:10.1086/499819 · Cited by 1,104
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
Bacterial Resistance to β-Lactam Antibiotics: Compelling Opportunism, Compelling Opportunity
Fisher, J. F., Meroueh, S. O., & Mobashery, S. (2005) · Chemical Reviews · doi:10.1021/cr030102i · Cited by 913
Bacterial resistance to antibiotics: Enzymatic degradation and modification
WRIGHT, G. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.04.002 · Cited by 897
Trends in antimicrobial drug development: Implications for the future
Spellberg, B., Powers, J. H., Brass, E. P., Miller, L. G., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/420937 · Cited by 867
The biology and future prospects of antivirulence therapies
Cegelski, L., Marshall, G. R., Eldridge, G. R., & Hultgren, S. J. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1818 · Cited by 788
“However, the commercialization of new classes of antibiotics over the past 20 years has not met expectations, and current pharmaceutical pipelines lack new, broad-spectrum antibiotic”
BackgroundAntibiotics produced by Streptomyces
de Lima Procópio, R. E., da Silva, I. R., Martins, M. K., de Azevedo, J. L., & de Araújo, J. M. (2012) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2012.08.014 · Cited by 735
Combating Antimicrobial Resistance: Policy Recommendations to Save Lives
Infectious Diseases Society of America (IDSA) (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir153 · Cited by 733
Antibacterial Natural Products in Medicinal Chemistry—Exodus or Revival?
von Nussbaum, F., Brands, M., Hinzen, B., Weigand, S., & Häbich, D. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200600350 · Cited by 672
The crisis of no new antibiotics—what is the way forward?
Piddock, L. J. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70316-4 · Cited by 500
Lack of development of new antimicrobial drugs: a potential serious threat to public health
Norrby, S. R., Nord, C. E., & Finch, R. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)01283-1 · Cited by 491
Natural products to drugs: natural product derived compounds in clinical trials
Butler, M. S. (2005) · Natural Product Reports · doi:10.1039/b402985m · Cited by 491
Staphylococcus aureus : superbug, super genome?
Lindsay, J. A., & Holden, M. T. G. (2004) · Trends in Microbiology · doi:10.1016/j.tim.2004.06.004 · Cited by 465
Strategies to Minimize Antibiotic Resistance
Lee, C.-R., Cho, I., Jeong, B., & Lee, S. (2013) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph10094274 · Cited by 446
Antibiotic-Resistant Bacteria: A Challenge for the Food Industry
Capita, R., & Alonso-Calleja, C. (2013) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2010.519837 · Cited by 434
THE MAGIC BULLETS AND TUBERCULOSIS DRUG TARGETS
Zhang, Y. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.100120 · Cited by 432
Current Epidemiology and Growing Resistance of Gram-Negative Pathogens
Livermore, D. M. (2012) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2012.27.2.128 · Cited by 417
Nathan, C. (2004) · Nature · doi:10.1038/431899a · Cited by 410
Marine actinobacteria: new opportunities for natural product search and discovery
Bull, A. T., & Stach, J. E. M. (2007) · Trends in Microbiology · doi:10.1016/j.tim.2007.10.004 · Cited by 391
Cherkasov, A., Hilpert, K., Jenssen, H., Fjell, C. D., Waldbrook, M., Mullaly, S. C., Volkmer, R., & Hancock, R. E. W. (2009) · ACS Chemical Biology · doi:10.1021/cb800240j · Cited by 357
Natural products — The future scaffolds for novel antibiotics?
Butler, M. S., & Buss, A. D. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.10.012 · Cited by 337
Antibiotics, Resistome and Resistance Mechanisms: A Bacterial Perspective
Sultan, I., Rahman, S., Jan, A. T., Siddiqui, M. T., Mondal, A. H., & Haq, Q. M. R. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02066 · Cited by 320
A rapid antimicrobial susceptibility test based on single-cell morphological analysis
Choi, J., Yoo, J., Lee, M., Kim, E.-G., Lee, J. S., Lee, S., Joo, S., Song, S. H., Kim, E.-C., Lee, J. C., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009650 · Cited by 311
Hamad, B. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3267 · Cited by 294
Discovery research: the scientific challenge of finding new antibiotics
Livermore, D. M., on behalf of the British Society for Antimicrobial Chemotherapy Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development, Blaser, M., Carrs, O., Cassell, G., Fishman, N., Guidos, R., Levy, S., Powers, J., Norrby, R., et al. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr262 · Cited by 284
Self-citationWhy big pharma has abandoned antibiotics
Plackett, B. (2020) · Nature · doi:10.1038/d41586-020-02884-3 · Cited by 278
Winn, M., Goss, R. J. M., Kimura, K.-I., & Bugg, T. D. H. (2010) · Nat. Prod. Rep. · doi:10.1039/b816215h · Cited by 277
The Concept of an Ideal Antibiotic: Implications for Drug Design
Gajdács, M. (2019) · Molecules · doi:10.3390/molecules24050892 · Cited by 271
Minimising antibiotic resistance
Livermore, D. M. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70166-3 · Cited by 268
Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review
Kakasis, A., & Panitsa, G. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.09.004 · Cited by 261
Hu, Y., Chen, J., Hu, G., Yu, J., Zhu, X., Lin, Y., Chen, S., & Yuan, J. (2015) · Marine Drugs · doi:10.3390/md13010202 · Cited by 260
Systems-level antimicrobial drug and drug synergy discovery
Roemer, T., & Boone, C. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1205 · Cited by 159
Antibiotic research in the age of omics: from expression profiles to interspecies communication
Wecke, T., & Mascher, T. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr373 · Cited by 62
Metadata
- Authors
- Projan, S. J.
- Venue
- Current Opinion in Microbiology
- Publisher
- Elsevier BV
- Published
- 2003-10
- Volume
- 6
- Issue
- 5
- Pages
- 427-430
- ISSN
- 1369-5274 (ISSN-L)
- OpenAlex
- W2052972684
- Cited by
- 503
- References
- 3
- FWCI
- 62.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.